Market Focus
US stock advanced on Thursday amid risk-on market sentiment, closing at all-time high and rose for a third day as investors considered that the economic recovery can resist the impact of the Omicron coronavirus variant. On Thursday, Merck & Co.’s Covid-19 pill was cleared by US regulators, giving high-risk patients another option for emergency use. Early trials also suggest that Merck’s molnupiravir could reduce mortality and hospitalisation rates in at-home patients by as much as 50%. In fact, people infected with Omicron are 50% to 70% less likely than those with Delta to be admitted to hospitals. Therefore, the positive news about Omicron variant and the announcement of the Merck & Co. approval both acted as a tailwind for the stock market. On top of that, the above news has also eased pressure on European authorities to lockdown their economies in order to curb epidemic transmission.
The benchmarks, S&P 500, Nasdaq 100 and the Dow Jones Industrial Average both rose on Thursday as risk appetite in US equities market has been boosted due to the news of the recent approval of two at-home Covid-19 treatment pills. Trading volume was low ahead of the Christmas holidays. S&P 500 was up 0.6% on a daily basis and the Dow Jones Industrial Average also advanced with a 0.5% gain for the day. Nine out of eleven sectors stayed in positive territory as the consumer discreet and industrials sectors are the best performing among all groups, rising 1.24% and 1.16%, respectively. The Nasdaq 100 climbed the most with 0.8% gain on Thursday and the MSCI World index rose 0.8%. The S&P 500 CBOE volatility index fell another half a point and trades at monthly lows close to 18.00 level.
Main Pairs Movement:
The US dollar declined on Thursday, staying in negative territory for the fourth consecutive day amid risk-on market mood despite rising US bond yields. The DXY index reached a daily top in late European session, then pulled back to near 96.00 level while surrendered most of its intraday’s gains. The US Food and Drug Administration announced that it had approved a second Covid-19 treatment pill for at-home use, which helped stoke risk appetite on Thursday and weighed on the safe-haven greenback. On economic data’s front, US consumer sentiment increased in December and new homes sales also climbed to a seven-month high.
GBP/USD advanced 0.43% on Thursday amid bearish momentum witnessed in US dollar across the board. The news that the UK was unlikely to implement tougher Covid-19 curbs after Christmas had lend support to the British pounds. The cable touched a daily high above 1.343 level in early American session, now trading at 1.3409 at the time of writing. Meanwhile, EUR/USD dropped to a daily low under 1.130 level but then rebounded modestly to offset some of its intraday’s losses. The pair was down 0.02% for the day.
Gold advanced and touched a daily top above $1810 during American session, as the broad US dollar weakness continued to pushed the precious metal higher. Meanwhile, WTI oil surged almost 1.0% for the day amid optimism that the hit to oil’s demand from Omicron won’t be as bad as initially feared.
Technical Analysis:
The precious metal, gold, steadily trades above 1800, trading at 1809 as the time of writing. Gold looks to head toward the immediate hurdle at 1815, retest its monthly high on the 4- hour chart. The resistance at 1815 is consider as a strong static barrier as gold attempts it three times within 2 months, but it ends up failing to break through. Thus, a break though the level would likely signal a firmer upward momentum. However, it would be difficult as the RSI has almost reached the overbought readings. On the downside, if gold falls below 1800, then it will turn to neutral mode from bullish mode. Overall, the risk is skewed to the upside as long as gold can hold above 1800.
Resistance: 1815, 1829, 1848
Support: 1800, 1782, 1770, 1765, 1753.
The major indices, including Nasdaq 100, rose for a third successive day as the markets less fear the Omicron and celebrate for Christmas. From the technical aspect, a three consecutive day upside momentum has brought Nasdaq 100 back to a bullish stance on the daily chart as it trades above all 5, 10, 20, 60 SMAs, suggesting a bullish trend. Nasdaq 100 has overall reclaim strength as the MACD is turning from negative to positive while the RSI is still far away from the overbought territory, entailing that buyers are in control. Most importantly, the double bottom pattern has been formed, which implies that sellers have given up and they are unable to push price downward. Consequently, the formation of the double bottom signifies a potential bullish reversal signal, heading to the next resistance at 16457, followed by the peak, 16796.
Resistance: 16457
EURUSD remains under modest price action, slightly turning upside after the US Core PCE Inflation jumped to 4.7% in November. From the technical perspective, EURUSD is still stuck in 1.1233- 1.1357 price range of the late November slide. In the near- term, the currency pair leans to bullish side as it trades within the upper bounce of Bollinger band, suggesting a potential upside momentum. In the meantime, the price action continues to remain above the 20 and 50 SMAs. To the upside, EURUSD needs to climb above the resistance at 1.1357 in order to turn from neutral- to- bullish, followed by the resistance at 1.1462. On the flip side, the bearish case can gain momentum on a break below the SMAs and 1.1233, followed by the support at 1.1186.
Resistance: 1.1357, 1.1462, 1.1548
Support: 1.1233, 1.1186
Economic Data: No Economic Calendar Due to Christmas Eve
Currency |
Data |
Time (GMT + 8) |
Forecast |
|
Éducation
Avertissement sur les risques: Le trading des contrats sur la différence (CFD) comporte un niveau de risque élevé et peut ne pas convenir à tous les investisseurs. L'effet de levier dans le trading des CFDs peut amplifier les gains et les pertes, et potentiellement dépasser votre capital initial. Il est essentiel de bien comprendre et de reconnaître les risques associés avant de trader sur les CFDs. Tenez compte de votre situation financière, de vos objectifs d'investissement et de votre tolérance au risque avant de prendre des décisions de trading. Les performances passées ne sont pas indicatives des résultats futurs. Consultez nos documents juridiques pour une compréhension complète des risques liés au trading des CFD.
Les informations figurant sur ce site sont générales et ne tiennent pas compte de vos objectifs, de votre situation financière ou de vos besoins particuliers. VT Markets ne peut être tenu responsable de la pertinence, de l'exactitude, de l'actualité ou de la complétude des informations contenues dans ce site.
Nos services et les informations contenues sur ce site ne sont pas fournis aux résidents de certains pays, notamment les États-Unis, Singapour, la Russie et les juridictions figurant sur les listes du FATF et des sanctions mondiales. Ils ne sont pas destinés à être distribués ou utilisés dans un endroit où une telle distribution ou utilisation contreviendrait à la législation ou à la réglementation locale.
VT Markets est une société qui regroupe plusieurs entités autorisées et enregistrées dans différentes juridictions.
· VT Global Pty Ltd est autorisée et réglementée par la Australian Securities & Investments Commission (ASIC) sous le numéro de licence 516246.
· VT Global n'est pas un émetteur ou un teneur de marché de produits dérivés et est uniquement autorisé à fournir des services aux clients professionnels.
· VT Markets (Pty) Ltd est un fournisseur de services financiers autorisé (FSP) enregistré et réglementé par la Financial Sector Conduct Authority (FSCA) d'Afrique du Sud sous le numéro de licence 50865.
· VT Markets Limited est un courtier en investissements autorisé et réglementé par la Mauritius Financial Services Commission (FSC) sous le numéro de licence GB23202269.
· VTMarkets Ltd, enregistrée en République de Chypre sous le numéro d'enregistrement HE436466 et adresse enregistrée à Archbishop Makarios III, 160, Étage 1, 3026, Limassol, Chypre.
Copyright © 2024 VT Markets.